ClinGen

ClinGen
Name	ClinGen
Formation	2013
Type	Consortium
Purpose	Clinical genome interpretation
Headquarters	United States
Region served	International

ClinGen The Clinical Genome Resource provides a centralized effort to define the clinical relevance of genes and variants for use in precision medicine and genomics. It brings together expertise from research centers, universities, hospitals, professional societies, and government agencies to curate evidence, develop standards, and disseminate knowledge supporting patient care. Participants include investigators from major academic medical centers, regulatory bodies, and professional organizations collaborating across translational research and clinical genomics.

Overview

ClinGen operates as a consortium linking contributors from institutions such as National Institutes of Health, National Human Genome Research Institute, Harvard University, Stanford University, Johns Hopkins University, Mayo Clinic, Massachusetts General Hospital, University of California, San Francisco, University of Pennsylvania, University of Washington, Broad Institute, Cold Spring Harbor Laboratory, Scripps Research, Duke University, Vanderbilt University Medical Center, Cleveland Clinic, Mount Sinai Health System, Columbia University Irving Medical Center, University of Michigan, University of Chicago, University of Pittsburgh Medical Center, University of Toronto, King's College London, University of Cambridge, University of Oxford, European Bioinformatics Institute, Wellcome Trust Sanger Institute, Genome Canada, Australian National University, University of Melbourne, Karolinska Institutet, Max Planck Society, National University of Singapore, University of Tokyo, Seoul National University Hospital, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Center, Northwestern University and other centers. It interfaces with professional societies such as the American College of Medical Genetics and Genomics, College of American Pathologists, American Society of Human Genetics, European Society of Human Genetics and regulatory agencies including the Food and Drug Administration and Centers for Medicare & Medicaid Services.

History and Development

Origins trace to initiatives funded by the National Institutes of Health and community efforts inspired by projects like the Human Genome Project, the 1000 Genomes Project, the Exome Aggregation Consortium, and programs at the Broad Institute. Early development involved collaborations with databases and consortia such as ClinVar, dbGaP, DECIPHER, HGMD, LOVD, Ensembl, UCSC Genome Browser, gnomAD, OMIM, GeneCards, HUGO Gene Nomenclature Committee, and projects led by centers like Wellcome Trust Sanger Institute and European Molecular Biology Laboratory. Key milestones included publication of curation frameworks and joint statements with organizations like the American College of Medical Genetics and Genomics and the American Medical Association.

Governance and Funding

ClinGen governance combines leadership from academic institutions, government programs, and non-profit organizations, with advisory input from stakeholders including World Health Organization, National Library of Medicine, National Cancer Institute, Patient-Centered Outcomes Research Institute, Bill & Melinda Gates Foundation, Wellcome Trust, Chan Zuckerberg Initiative, Robert Wood Johnson Foundation, European Commission, Genome Research Limited, and national health services such as NHS England. Boards and working groups include representation from clinical laboratories such as Quest Diagnostics, LabCorp, Invitae, Illumina, and research foundations including Howard Hughes Medical Institute. Funding sources have included grants from the National Institutes of Health, philanthropic awards from Gates Foundation partners, and institutional support from universities and health systems such as Mayo Clinic and Massachusetts General Hospital.

Clinical and Research Activities

ClinGen supports variant interpretation for conditions studied at institutions like Memorial Sloan Kettering Cancer Center for oncology, Boston Children's Hospital for rare disease pediatrics, Rady Children's Hospital San Diego for neonatal genomics, Fred Hutchinson Cancer Center for hematologic malignancies, and specialty centers such as Johns Hopkins Hospital and Cleveland Clinic for cardiovascular genetics. It collaborates on clinical trials and studies with entities including National Cancer Institute, European Organization for Research and Treatment of Cancer, Multiple Myeloma Research Foundation, Alzheimer's Association, American Heart Association, Susan G. Komen Foundation, American Diabetes Association, and rare disease networks like Global Genes. Research activities intersect with projects such as All of Us Research Program, Genomics England, Precision Medicine Initiative, 100,000 Genomes Project, Personalized Medicine Coalition, and repository efforts at National Center for Biotechnology Information.

Data Resources and Tools

ClinGen curates resources integrated with platforms including ClinVar, dbSNP, RefSeq, UniProt, GTEx, Trans-Omics for Precision Medicine Program, ArrayExpress, Sequence Read Archive, European Nucleotide Archive, BioPortal, BioSamples, Gene Ontology Consortium, and tooling from Global Alliance for Genomics and Health. It develops expert-reviewed gene-disease validity assertions, variant pathogenicity classifications, and gene dosage sensitivity maps, and provides interfaces compatible with software from Ensembl, UCSC Genome Browser, IGV (Integrative Genomics Viewer), CIViC, Variant Effect Predictor, SnpEff, BCBio, and workflow systems like Galaxy, Nextflow, and Cromwell.

Standards and Guidelines

ClinGen has contributed to consensus frameworks alongside organizations such as the American College of Medical Genetics and Genomics, Association for Molecular Pathology, World Health Organization, International League Against Epilepsy, Human Variome Project, Global Alliance for Genomics and Health, European Society of Human Genetics, Clinical Genome Resource Consortium, Clinical Laboratory Improvement Amendments, and standards bodies including ISO and National Institute of Standards and Technology. These efforts cover variant classification, gene-disease validity, data sharing policies, informed consent, and reporting for clinical laboratories and research programs.

Impact and Criticism

ClinGen's outputs influence clinical reporting, guideline development, and regulatory policy, informing actions at organizations such as Food and Drug Administration, Centers for Medicare & Medicaid Services, American College of Medical Genetics and Genomics, College of American Pathologists, American Medical Association, and payers including Centers for Medicare & Medicaid Services contractors. Criticisms have focused on challenges shared with initiatives like ClinVar and gnomAD: representativeness of populations (as discussed by 1000 Genomes Project critiques), curation bottlenecks highlighted in assessments of Human Gene Mutation Database, data harmonization issues raised in debates about dbGaP and Genomics England, and sustainability concerns echoing conversations involving Wellcome Trust and Bill & Melinda Gates Foundation. Ongoing discourse engages stakeholders from patient advocacy groups and consortia such as Global Alliance for Genomics and Health and Global Genes about transparency, equity, and clinical utility.

Category:Genomics